Yahoo Finance15d
Is Scholar Rock Holding (SRRK) One of the Oversold Biotech Stocks to Buy Now?
In this article, we are going to take a look at where Scholar Rock Holding Corporation (NASDAQ:SRRK) stands against other oversold biotech stocks to buy now. Biotechnology stocks are among the ...
Yahoo Finance4d
Scholar Rock Holding Corporation (SRRK)
CAMBRIDGE, Mass., February 27, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA ...
Morningstar24d
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders ...
ETF Daily News18d
Scholar Rock (SRRK) Expected to Announce Earnings on Thursday
Scholar Rock has a 52 week low of $6.76 and a 52 week high of $46.98. The firm has a 50 day simple moving average of $41.89 and a 200 day simple moving average of $28.17. Get Scholar Rock alerts: ...
Business Wire1mon
Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...
Business Wire18d
Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...
Principal Financial Group Inc. Buys New Position in Scholar Rock Holding Co. (NASDAQ:SRRK)
Principal Financial Group Inc. bought a new stake in shares of Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with ...
Benzinga.com5mon
Scholar Rock Holding Stock Price, Quotes and Forecasts | NASDAQ:SRRK | Benzinga
Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth Scholar Rock aims for a 2025 launch of apitegromab in SMA, expecting $2 billion in global ...
Morningstar1mon
Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition
She joins Scholar Rock’s Executive Team ... she had roles of increasing responsibility at Mersana Therapeutics, Shire, and Boston Scientific. She graduated from Ithaca College with a degree ...
Hosted on MSN2mon
SA Asks: Which biotechs are most likely to be acquired near-term?
Sarepta Therapeutics (NASDAQ ... Huntington’s disease candidate advances towards potential FDA approval; Scholar Rock (NASDAQ:SRRK), which has a late-stage spinal muscular atrophy drug and ...
Nasdaq1mon
Scholar Rock Holding Reaches Analyst Target Price
In recent trading, shares of Scholar Rock Holding Corp (Symbol: SRRK) have crossed above the average analyst 12-month target price of $44.00, changing hands for $44.32/share. When a stock reaches ...